Relay Therapeutics Inc [NASDAQ: RLAY] price surged by 7.42 percent to reach at $0.23.
The one-year RLAY stock forecast points to a potential upside of 80.86. The average equity rating for RLAY stock is currently 1.42, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Relay Therapeutics Inc [RLAY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RLAY shares is $17.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RLAY stock is a recommendation set at 1.42. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Relay Therapeutics Inc shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on April 17, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price from $10.60 to $16. The new note on the price target was released on September 10, 2024, representing the official price target for Relay Therapeutics Inc stock. Previously, the target price had yet another raise to $20, while Goldman analysts kept a Buy rating on RLAY stock.
The Average True Range (ATR) for Relay Therapeutics Inc is set at 0.27, with the Price to Sales ratio for RLAY stock in the period of the last 12 months amounting to 56.72. The Price to Book ratio for the last quarter was 0.72, with the Price to Cash per share for the same quarter was set at 4.58.
RLAY Stock Performance Analysis:
Relay Therapeutics Inc [RLAY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.07. With this latest performance, RLAY shares gained by 27.10% in over the last four-week period, additionally sinking by -44.68% over the last 6 months – not to mention a drop of -47.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RLAY stock in for the last two-week period is set at 61.22, with the RSI for the last a single of trading hit 68.62, and the three-weeks RSI is set at 55.64 for Relay Therapeutics Inc [RLAY]. The present Moving Average for the last 50 days of trading for this stock 3.08, while it was recorded at 3.22 for the last single week of trading, and 5.28 for the last 200 days.
Insight into Relay Therapeutics Inc Fundamentals:
Relay Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.95 and a Current Ratio set at 15.95.
RLAY Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RLAY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Relay Therapeutics Inc go to 2.09%.
Relay Therapeutics Inc [RLAY] Institutonal Ownership Details
There are presently around $103.52%, or 105.44%% of RLAY stock, in the hands of institutional investors. The top three institutional holders of RLAY stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 27.9 million shares, which is approximately 21.0093%. VANGUARD GROUP INC, holding 11.7 million shares of the stock with an approximate value of $$76.32 million in RLAY stocks shares; and VANGUARD GROUP INC, currently with $$68.74 million in RLAY stock with ownership which is approximately 7.9375%.
